Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX Effects on Seizure Severity and Susceptibility
NCT05605756Phase 4Terminated
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A in focal epilepsy, sponsored by Beth Israel Deaconess Medical Center. Started Mar 2023; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
focal epilepsy
Beyond the preview
Go deeper on NCT05605756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605756.